BioCentury | Apr 18, 2019
Translation in Brief

Agenus scales the AI ALPS

...second line cervical cancer. In addition to checkpoint inhibitors, Agenus is evaluating its cancer vaccine AutoSynVax...
BioCentury | Jul 6, 2017
Clinical News

BioNTech, Neon teams report personalized cancer vaccine data

...NASDAQ:AGEN), Advaxis Inc. (NASDAQ:ADXS) and Aduro Biotech Inc. (NASDAQ:ADRO) (see BioCentury Innovations, March 16) . Mary Romeo AutoSynVax Keytruda Opdivo Aduro...
BioCentury | Apr 28, 2017
Company News

Agenus restructuring news

...which target PD-1 and cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ; CD152), and its AutoSynVax...
...and Lexington, Mass. The company will also focus on its manufacturing operations in Berkeley, Calif. AutoSynVax...
...and a 12-month operating loss of $107.5 million. Agenus Inc. (NASDAQ:AGEN), Lexington, Mass. Business: Cancer Chris Lieu AutoSynVax Agenus...
BioCentury | Apr 7, 2017
Clinical News

AutoSynVax: Ph I started

...Agenus began an open-label, U.S. Phase I trial to evaluate 240 µg subcutaneous AutoSynVax plus the...
...for up to 1 year in about 20 patients. Agenus Inc. (NASDAQ:AGEN), Lexington, Mass. Product: AutoSynVax...
...PFS), objective response rate (ORR) and T cell response Status: Phase I started Milestone: NA Julian Zhu AutoSynVax Agenus...
BioCentury | Mar 16, 2017
Product R&D

Neo wave

...nivolumab. Agenus Inc. has begun recruiting for a Phase I trial of its neoantigen vaccine AutoSynVax...
...DNA encoding neoantigens Cancer IND Yvonne Paterson, University of Pennsylvania Publicly traded Agenus Inc. (NASDAQ:AGEN) AutoSynVax...
BioCentury | Feb 23, 2017
Company News

Agenus pointing to its checkpoint inhibitors

...to develop other cancer vaccine candidates. The company will begin clinical testing this year of AutoSynVax...
...patient’s cancer antigens with heat shock protein 70 (Hsp70) . The company plans to evaluate AutoSynVax...
...Thursday. Jaime De Leon AGEN1884 HSPPC-96 Prophage Agenus Inc. Cytotoxic T-lymphocyte associated protein 4 (CTLA4) (CD152) Programmed cell death 1 (PD-1) (PDCD1) (CD279) AGEN2034 AutoSynVax PhosphoSynVax Prophage...
BioCentury | Jan 4, 2016
Company News

PhosImmune, Agenus deal

...appear as foreign to the immune system. Agenus said that PTTs are synergistic with Agenus’ AutoSynVax...
Items per page:
1 - 7 of 7